TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating on February 25.
Marc Frahm has given his Buy rating due to a combination of factors including the promising clinical trial results and strategic initiatives by Scholar Rock Holding. The company’s recent Phase III SAPPHIRE trial for apitegromab in spinal muscular atrophy (SMA) showed significant improvements, which are expected to support a Biologics License Application (BLA) submission and a potential U.S. launch in the fourth quarter. These results indicate a strong likelihood of broad adoption of their anti-myostatin therapy, positioning Scholar Rock as a key player in the competitive SMA market.
Furthermore, the company is actively preparing for the launch by engaging with key stakeholders and building a robust sales and support team. Scholar Rock’s strategic plans also include expanding apitegromab’s development into other rare neuromuscular disorders, which could further enhance its market potential. The company’s financial position, with a substantial cash reserve, supports these initiatives, making it an attractive candidate for mergers and acquisitions. These elements collectively underpin Marc Frahm’s positive outlook and Buy rating for Scholar Rock Holding.